StageZero Life Sciences, Ltd Announces Results of Special Meeting

TORONTO, ON and RICHMOND, VA / ACCESSWIRE / December 10, 2021 / StageZero Life Sciences, Ltd. (TSX:SZLS)(OTCQB:SZLSF) ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, is pleased to report that shareholders today approved at a special meeting the issuance of 8,000,000 common shares of the Company to Health Clinics Limited. The share issuance is in connection with the Company's prior acquisition of all of the issued and outstanding shares of Clinic Operations Limited, a wholly-owned subsidiary of Health Clinics Limited ("Acquisition"). The issuance of these shares is contingent upon the achievement of certain milestones.

Of the Common Shares voted at the Meeting, 90.005% of the Common Shares were voted in favour of the Resolution.

Further details of the business considered at the meeting may be found in the Company's management information circular dated October 21, 2021 (the "Circular"). and posted on the System for Electronic Data Analysis and Retrieval (SEDAR) at www.sedar.com. Voting results are released in accordance with Toronto Stock Exchange ("TSX") requirements.

About StageZero Life Sciences, Ltd.
StageZero Life Sciences, Ltd. is a vertically integrated healthcare company dedicated to improving the early detection and management of cancer and other chronic diseases through next-generation diagnostics and a unique telehealth program that provides clinical interventions to help patients reduce the risk of developing late-stage disease (AVRT™).

The Company's next generation test, Aristotle®, is the first-ever mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle® uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. This underlying technology has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.

Aristotle®, as well as additional cancer diagnostics (ColonSentry®, BreastSentry™, and the Prostate Health Index) are processed at the Company's clinical laboratory, StageZero Life Sciences, Inc., a CAP accredited and CLIA certified high-complexity reference laboratory in Richmond, Virginia. In addition, the Company is also leveraging its specialty in polymerase chain reaction (PCR) testing to provide COVID-19 PCR testing (swab and saliva) and Antibody Testing (blood analysis).

StageZero Life Sciences trades on the Toronto Stock exchange under the symbol SZLS and on the OTCQB under the symbol SZLSF.

Matthew Pietras
CFO & COO

Company Contacts:
Rebecca Greco
Investor Relations
[email protected]
Tel: 1-855-420-7140 Ext. 1838

SOURCE: StageZero Life Sciences Ltd